Abstract
Tauopathies, including Alzheimers disease, are neurodegenerative diseases characterized by the deposition of hyperphosphorylated tau protein in the central nervous system, and are the major cause of dementia in later life. Considerable advances have been made in developing mouse models that recapitulate, to varying extents, the development of human tau pathology, and the learning and memory deficits characteristic of some tauopathies. Furthermore, such models have been used to show promising disease-modifying effects in pre-clinical testing of new therapeutics. Various strategies have been utilised to generate mouse models of tauopathies. Some of the most enlightening models developed to date either constitutively or inducibly express pathogenic tau mutations. These animals have been instrumental in defining critical disease-related mechanisms, including the observation that tangles are not the toxic form of tau in disease. Here, we discuss the strengths and weaknesses of well characterised transgenic models that emulate human tauopathy, and include a comprehensive listing of the main phenotypic characteristics of all reported tau transgenic rodents. We summarise the use of tau mice for the development and evaluation of new therapeutic approaches, and their utility in identifying novel drug targets. In addition, we review the parameters to be considered in the development of the next generation of rodent models of tauopathy, aimed at further increasing our understanding of disease aetiology and in evaluating novel treatments.
Keywords: Tauopathy, neurofibrillary tangle, kinase, transgenic model, therapeutic, phosphorylation, phenotype, microtubule-associated protein tau, neurodegeneration, Alzheimer's disease
CNS & Neurological Disorders - Drug Targets
Title: Transgenic Mouse Models of Tauopathy in Drug Discovery
Volume: 9 Issue: 4
Author(s): W. Noble, D.P. Hanger and J.-M. Gallo
Affiliation:
Keywords: Tauopathy, neurofibrillary tangle, kinase, transgenic model, therapeutic, phosphorylation, phenotype, microtubule-associated protein tau, neurodegeneration, Alzheimer's disease
Abstract: Tauopathies, including Alzheimers disease, are neurodegenerative diseases characterized by the deposition of hyperphosphorylated tau protein in the central nervous system, and are the major cause of dementia in later life. Considerable advances have been made in developing mouse models that recapitulate, to varying extents, the development of human tau pathology, and the learning and memory deficits characteristic of some tauopathies. Furthermore, such models have been used to show promising disease-modifying effects in pre-clinical testing of new therapeutics. Various strategies have been utilised to generate mouse models of tauopathies. Some of the most enlightening models developed to date either constitutively or inducibly express pathogenic tau mutations. These animals have been instrumental in defining critical disease-related mechanisms, including the observation that tangles are not the toxic form of tau in disease. Here, we discuss the strengths and weaknesses of well characterised transgenic models that emulate human tauopathy, and include a comprehensive listing of the main phenotypic characteristics of all reported tau transgenic rodents. We summarise the use of tau mice for the development and evaluation of new therapeutic approaches, and their utility in identifying novel drug targets. In addition, we review the parameters to be considered in the development of the next generation of rodent models of tauopathy, aimed at further increasing our understanding of disease aetiology and in evaluating novel treatments.
Export Options
About this article
Cite this article as:
Noble W., Hanger D.P. and Gallo J.-M., Transgenic Mouse Models of Tauopathy in Drug Discovery, CNS & Neurological Disorders - Drug Targets 2010; 9 (4) . https://dx.doi.org/10.2174/187152710791556131
DOI https://dx.doi.org/10.2174/187152710791556131 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neurological Aspects of Medical Use of Cannabidiol
CNS & Neurological Disorders - Drug Targets Evaluation of Acetylcholinesterase and Prolyl Oligopeptidase Inhibition of Novel Amino acid-functionalized Stigmasterol and Ursolic Acid Derivatives
Current Organic Chemistry Correlation of Alzheimer-like Tau Hyperphosphorylation and fMRI Bold Intensity
Current Alzheimer Research Discovery of a Small Molecule Inhibitor of the Interaction Between HIV-1 Proteins and Cellular Cofactors: A Novel Candidate Anti-HIV-1 Drug
Current Chemical Biology Lifestyle and Genetic Contributions to Cognitive Decline and Hippocampal Structure and Function in Healthy Aging
Current Alzheimer Research Insulin Resistance, Non-alcoholic Fatty Liver Disease and Hepatitis C Virus Infection
Reviews on Recent Clinical Trials Histone Deacetylase Inhibitors: A Novel Therapeutic Approach to Huntingtons Disease (Complex Mechanism of Neuronal Death).
Current Alzheimer Research Familial Alzheimers Disease Mutations in Presenilin 1 Do Not Alter Levels of the Secreted Amyloid-β Protein Precursor Generated by β-Secretase Cleavage
Current Alzheimer Research Discovery and Optimization of Pyrazoline Derivatives As Promising Monoamine Oxidase Inhibitors
Current Topics in Medicinal Chemistry Editorial [Hot Topic: Nutrition and Alzheimers Disease: Is There Any Connection? (Guest Editor: C. Ramassamy)]
Current Alzheimer Research Functional and Structural Alterations of Large Arteries: Methodological Issues
Current Pharmaceutical Design Intracranial Atherosclerotic Stenosis is Related to Post-stroke Cognitive Impairment: A Cross-sectional Study of Minor Stroke
Current Alzheimer Research β3-Adrenergic Receptors: Really Relevant Targets for Anti-Obesity Drugs?
Current Medicinal Chemistry - Central Nervous System Agents Neurobiological Influences on Recovery from Traumatic Brain Injury: The Role of Genetic Polymorphisms
Current Pharmaceutical Design Genetic Editing and Pharmacogenetics in Current And Future Therapy Of Neurocognitive Disorders
Current Alzheimer Research Blood Brain Barrier Compromise with Endothelial Inflammation may Lead to Autoimmune Loss of Myelin during Multiple Sclerosis
Current Neurovascular Research Neurotrophins - From Pathophysiology to Treatment in Alzheimers Disease
Current Alzheimer Research Targeting Insulin Signaling for the Treatment of Alzheimer's Disease
Current Topics in Medicinal Chemistry Blood-Brain Barrier ABC-transporter P-glycoprotein in Alzheimer's Disease: Still a Suspect?
Current Pharmaceutical Design Meta-Analysis of the Effectiveness and Safety of Prophylactic Use of Nimodipine in Patients with an Aneurysmal Subarachnoid Haemorrhage
CNS & Neurological Disorders - Drug Targets